" /> Zansecimab - CISMeF





Preferred Label : Zansecimab;

NCIt definition : A humanized and engineered immunoglobulin G4 (IgG4) isotype monoclonal antibody against the proangiogenic cytokine angiopoietin 2 (Ang2), with potential anti-angiogenic activity. Upon administration, zansecimab targets and binds to Ang2. This prevents the binding of Ang2 to its endothelial cell-specific receptor TEK tyrosine kinase (Tie2). This prevents Tie2-mediated signaling and results in an inhibition of Tie2-expressing, tumor-stimulated endothelial cell proliferation, which prevents angiogenesis and inhibits tumor cell proliferation. In addition, Ang2 is elevated in acute respiratory distress syndrome (ARDS), and targeting Ang2 may prevent or slow ARDS progression.;

UNII : A67ZN01CAW;

CAS number : 2415205-37-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2415205-37-5 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : LY 3127804; LY-3127804;

NCI Metathesaurus CUI : CL1642853;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
21/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.